Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RenovoRx, Inc.RNXT · Entity 6797 | Chief Operating Officer | January 19, 2024 | January 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RenovoRx, Inc.
Report date January 19, 2024 · Filed January 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.08 | Direct | 33,768 |
Reported balance
After 2024-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-19 · Grant · Acquired 33,768 · Balance 33,768 F1: On January 19, 2024, the Reporting Person was awarded a stock bonus of 33,768 shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). These shares were fully vested upon issuance to the Reporting Person, and expire on January 19, 2034. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.08 | Direct | 125,132 |
Reported balance
After 2024-01-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-19 · Grant · Acquired 125,132 · Balance 125,132 F2: On January 19, 2024, the Reporting Person received a nonqualified stock option grant for a total of 125,132 shares of common stock vesting over four years at a rate of 1/48 per month with no cliff, beginning vesting on February 1, 2024. The option will become fully vested and exercisable on February 1, 2028, and expires on January, 19, 2034. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 19, 2024, the Reporting Person was awarded a stock bonus of 33,768 shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). These shares were fully vested upon issuance to the Reporting Person, and expire on January 19, 2034.
F2: On January 19, 2024, the Reporting Person received a nonqualified stock option grant for a total of 125,132 shares of common stock vesting over four years at a rate of 1/48 per month with no cliff, beginning vesting on February 1, 2024. The option will become fully vested and exercisable on February 1, 2028, and expires on January, 19, 2034.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2024 Filed Jan 24, 2024 02:50 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option · Derivative | 125,132 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001493152-24-003519 · ownership.xml · derivative · entry 2 Nelms Angela · CIK 0001946374 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,132 Underlying: Common Stock · 125,132 shares Expires not disclosed F2 · derivative.exercise_date: On January 19, 2024, the Reporting Person received a nonqualified stock option grant for a total of 125,132 shares of common stock vesting over four years at a rate of 1/48 per month with no cliff, beginning vesting on February 1, 2024. The option will become fully vested and exercisable on February 1, 2028, and expires on January, 19, 2034. F2 · derivative.expiration_date: On January 19, 2024, the Reporting Person received a nonqualified stock option grant for a total of 125,132 shares of common stock vesting over four years at a rate of 1/48 per month with no cliff, beginning vesting on February 1, 2024. The option will become fully vested and exercisable on February 1, 2028, and expires on January, 19, 2034. Read SEC document |
| January 19, 2024 Filed Jan 24, 2024 02:50 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option · Derivative | 33,768 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001493152-24-003519 · ownership.xml · derivative · entry 1 Nelms Angela · CIK 0001946374 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,768 Underlying: Common Stock · 33,768 shares Expires not disclosed F1 · derivative.exercise_date: On January 19, 2024, the Reporting Person was awarded a stock bonus of 33,768 shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). These shares were fully vested upon issuance to the Reporting Person, and expire on January 19, 2034. F1 · derivative.expiration_date: On January 19, 2024, the Reporting Person was awarded a stock bonus of 33,768 shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). These shares were fully vested upon issuance to the Reporting Person, and expire on January 19, 2034. Read SEC document |
| October 03, 2023 Filed Oct 4, 2023 20:44 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 800 | $1.05 | $836.00 |
DisclosureSEC source: 0001493152-23-035684 · ownership.xml · nonDerivative · entry 2 Nelms Angela · CIK 0001946374 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Read SEC document |
| October 03, 2023 Filed Oct 4, 2023 20:44 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 300 | $1.05 | $314.97 |
DisclosureSEC source: 0001493152-23-035684 · ownership.xml · nonDerivative · entry 1 Nelms Angela · CIK 0001946374 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300 Read SEC document |
| March 15, 2023 Filed Mar 29, 2023 20:54 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantEmployee Stock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001493152-23-009489 · ownership.xml · derivative · entry 1 Nelms Angela · CIK 0001946374 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2033-03-15 F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on January 1, 2023. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:14 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantEmployee Stock Option (right to buy) · Derivative | 274,230 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-22-050898 · doc4.xml · derivative · entry 1 Nelms Angela · CIK 0001946374 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,230 Underlying: Common Stock · 274,230 shares Expires 2032-09-19 F1 · derivative.exercise_date: One-fourth of the shares subject to the option vest on September 19, 2023 and 1/36th of the remaining shares vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.